JCV-specific cellular immune response correlates with a favorable clinical outcome in HIV-infected individuals with progressive multifocal leukoencephalopathy

References

• Achim CL, Wiley CA (1992). Expression of major his-tocompatibility complex antigens in the brains of patients with progressive multifocal leukoencephalopa-thy. J Neuropathol Exp Neural 51: 257–263.
   Google Scholar
• Altman JD, Moss PAH, Goulder PJR, Barouch DH, McHeyzer-Williams MG, Bell JI, McMichael AJ, Davis MM (1996). Phenotypic analysis of antigen-specific T lymphocytes [published erratum appears in science 1998 Jun 19; 280(5371):1821]. Science 274: 94–96.
   Google Scholar
• Berner B, Krieter DH, Rumpf KW, Grunewald RW, Beuche W, Weber T, Muller GA (1999). Progressive multifo-cal leukoencephalopathy in a renal transplant patient diagnosed by JCV-specific DNA amplification and an intrathecal humoral immune response to recombinant virus protein 1. Nephrol Dial Transplant 14: 462–465.
   Google Scholar
• Clifford DB, Yiannoutsos C, Glicksman M, Simpson DM, Singer EJ, Piliero PJ, Marra CM, Francis GS, McArthur JC, Tyler KL, Tselis AC, Hyslop NE (1999). HAART im-proves prognosis in HIV-associated progressive multi-focal leukoencephalopathy [see comments]. Neurology 52: 623–625.
   PubMed Web of Science ®Google Scholar
• Coleman DV, Gardner SD, Mulholland C, Fridiksdottir V, Porter AA, Lilford R, Valdimarsson H (1983). Human polyomavirus in pregnancy. A model for the study of defence mechanisms to virus reactivation. Clin Exp lmmunol 53: 289–296.
   Google Scholar
• Ellison GW (1969). Progressive multifocal leukoen-cephalopathy (PML). Investigation of the immunologic status of a patient with lymphosarcoma and PML. J Neu-ropathol Exp Neurol 28: 501–506.
   Google Scholar
• Gasnault J, Taoufik Y, Goujard C, Kousignian P, Abbed K, Boue F, Dussaix E, Delfraissy JF (1999). Pro-longed survival without neurological improvement in patients with AIDS-related progressive multifocal leukoencephalopathy on potent combined antiretrovi-ral therapy. J NeuroVirol 5: 421–429.
   PubMed Web of Science ®Google Scholar
• Guillaume B, Sindic CJ, Weber T (2000). Progressive mul-tifocal leukoencephalopathy: simultaneous detection of JCV DNA and anti-JCV antibodies in the cerebrospinal fluid. Eur J Neurol 7: 101–106.
   Google Scholar
• Horn GV, Bastian FO, Moake JL (1978). Progressive multifo-cal leukoencephalopathy: failure of response to transfer factor and cytarabine. Neurology 28: 794–797.
   Google Scholar
• Klein J, Sato A, (2000). The HLA system. First of two parts. N Engl J Med 343: 702–709.
   PubMed Web of Science ®Google Scholar
• Knight A, O'Brien P, Osoba D (1972). Spontaneous progres-sive multifocal leukoencephalopathy. Immunologic as-pects. Ann Intern Med 77: 229–233.
   Google Scholar
• Koralnik IJ, Boden D, Mai VX, Lord CI, Letvin NL (1999). JC virus DNA load in patients with and without pro-gressive multifocal leukoencephalopathy. Neurology 52: 253–260.
   Google Scholar
• Koralnik IJ, Du Pasquier RA, Letvin NL (2001). JC virus-specific cytotoxic T lymphocytes in individuals with progressive multifocal leukoencephalopathy. I Virol 75: 3483–3487.
   PubMed Web of Science ®Google Scholar
• Marriott PJ, O'Brien MD, Mackenzie IC, Janota I (1975). Progressive multifocal leucoencephalopathy: remission with cytarabine. J Neurol Neurosurg Psychiatry 38: 205–209.
   PubMedGoogle Scholar
• Mathews TH, Wisotzkey H, Moossy J (1976). Multiple cen-tral nervous system infections in progressive multifocal leukoencephalopathy. Neurology 26: 9–14.
   Google Scholar
• Meylan PR, Vuadens P, Mae der P, Sahli R, Tagan MC (1999). Monitoring the response of AIDS-related progressive multifocal leukoencephalopathy to HAART and cido-fovir by PCR for JC virus DNA in the CSF. Eur Neurol 41: 172–174.
   PubMed Web of Science ®Google Scholar
• Miralles P, Berenguer J, Garcia de Viedma D, Padilla B, Cosin J, Lopez-Bernaldo de Quiros JC, Munoz LS, Moreno S, Bouza E (1998). Treatment of AIDS-associated progressive multifocal leukoencephalopathy with highly active antiretroviral therapy. AIDS 12: 2467–2472.
   PubMed Web of Science ®Google Scholar
• Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH, Castro-Malaspina H, Childs BH, Gillio AP, Small TN, et al (1994). Infusions of donor leukocytes to treat Epstein-Barr virus-associated lym-phoproliferative disorders after allogeneic bone marrow transplantation. N Engl I Med 330: 1185–1191.
   PubMed Web of Science ®Google Scholar
• Tassie JM, Gasnault J, Bentata M, Deloumeaux J, Boue F, Billaud E, Costagliola D (1999). Survival improve-ment of AIDS-related progressive multifocal leukoen-cephalopathy in the era of protease inhibitors. Clinical Epidemiology Group. French Hospital Database on HIV. AIDS 13: 1881–1887.
   Google Scholar
• Walker DL, Padgett BL (1983). The epidemiology of human polyomaviruses. Prog Clin Biol Res 105: 99–106.
   PubMedGoogle Scholar
• Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, Riddell SR (1995). Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 333: 1038–1044.
   PubMed Web of Science ®Google Scholar
• Weber J (2000). Melanoma peptide vaccines: from preclin-ical background to clinical trials. Curr Oncol Rep 2: 38–47.
   PubMedGoogle Scholar
• Weber TC, Trebst C, Frye S, Cinque P, Vago L, Sindic CJ, Schulz-Schaeffer WJ, Kretzschmar HA, Enzensberger W, Hunsmann G, Luke W (1997). Analysis of the systemic and intrathecal humoral immune response in progres-sive multifocal leukoencephalopathy. I Infect Dis 176: 250–254.
   PubMed Web of Science ®Google Scholar
• Willoughby E, Price RW, Padgett BL, Walker DL, Dupont B (1980). Progressive multifocal leukoencephalopathy (PML): In vitro cell-mediated immune responses to mi-togens and JC virus. Neurology 30: 256–262.
   Google Scholar